Unknown

Dataset Information

0

Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-?B inhibitor for antitumor immunotherapy.


ABSTRACT: The response to programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) blockade in cancer immunotherapy is limited because of multiple immune evasion mechanisms. Here, a previously unknown strategy is proposed to synergize the nuclear factor ?B (NF-?B) inhibition and PD-1 blockade for antitumor immunotherapy. A dual pH-sensitive nanocarrier loading curcumin (CUR) and anti–PD-1 monoclonal antibody (aPD-1) may bind to circulating PD-1+ T cells and then follow their infiltration into the tumor. Furthermore, the nanodrug bound to PD-1+ T cells may be released in the tumor microenvironment, leaving aPD-1 to block PD-1 on T cells and generating a CUR-encapsulated cationic nanodrug that can be easily taken up by tumor cells/tumor associated macrophages (TAMs). Thus, not only the antitumor T cells mediate efficient CUR delivery to tumor but also the efficient CUR delivery promotes the tumor infiltration of antitumor T cells, thereby resulting in effective activation of antitumor immunity.

SUBMITTER: Xiao Z 

PROVIDER: S-EPMC7002126 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7778587 | biostudies-literature
| S-EPMC9806143 | biostudies-literature
| S-EPMC9322126 | biostudies-literature
| S-EPMC6209395 | biostudies-literature
| S-EPMC6380009 | biostudies-literature
| S-EPMC6599972 | biostudies-literature
| S-EPMC6718162 | biostudies-literature
| S-EPMC10050415 | biostudies-literature
| S-EPMC5572324 | biostudies-literature
| S-EPMC10030802 | biostudies-literature